Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Keryx Biopharmaceuticals Adds Three Clinical-Stage Oncology Drug Candidates to its Pipeline, Including a Novel, First-in-Class, Oral AKT-Inhibitor In Phase II Signs Agreement to Acquire...
Keryx Biopharmaceuticals, Inc. News NEW YORK, Dec. 19 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), today announced that application has been made for block admission to trading on...
Keryx Biopharmaceuticals, Inc. News NEW YORK, Nov. 26 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), today announced that application has been made to the London Stock Exchange for...
Keryx Biopharmaceuticals, Inc. Announces S.O.A.R. (Sulodexide Open Access Research) Program Collaboration with the University of Michigan Top researcher to explore potential beneficial effects of...
Keryx Biopharmaceuticals, Inc. Raises $15 Million In Private Equity Transaction With Institutional Investors NEW YORK, Nov. 18 / -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), a...
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2003 Financial Results - Keryx to Hold Investor Conference Call Tomorrow, Tuesday, November 11, 2003 at 10:00 AM EST - NEW YORK, Nov. 10...
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2003 Financial Results on Tuesday, November 11, at 10:00 a.m. EST NEW YORK, Nov. 7 -- Keryx Biopharmaceuticals, Inc...
REMINDER: Keryx Biopharmaceuticals CEO to Provide KRX-101 Update Today at the Rodman & Renshaw Techvest Healthcare Conference NEW YORK, Oct. 21 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX;...
Keryx Biopharmaceuticals, Inc. Initiates Phase II/III Clinical Program of KRX-101 (Sulodexide Gelcaps) for Treatment of Diabetic Nephropathy KRX-101 has FDA Fast-Track Designation To Treat A...
Keryx Biopharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference NEW YORK, Oct. 16 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX, London AIM: KRX), a biopharmaceutical...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.1 | -1.56028368794 | 70.5 | 71.099999 | 69 | 12 | 69.45555544 | DE |
| 4 | -1.05 | -1.49041873669 | 70.45 | 72.95 | 67.4 | 101 | 70.54181571 | DE |
| 12 | -10.449999 | -13.0870371082 | 79.849999 | 84.55 | 67.4 | 96 | 73.95445556 | DE |
| 26 | -13.15 | -15.9297395518 | 82.55 | 88.65 | 67.4 | 102 | 78.08281339 | DE |
| 52 | -6.12 | -8.10381355932 | 75.52 | 92.55 | 67.4 | 115 | 79.99276893 | DE |
| 156 | -6.12 | -8.10381355932 | 75.52 | 92.55 | 67.4 | 115 | 79.99276893 | DE |
| 260 | -6.12 | -8.10381355932 | 75.52 | 92.55 | 67.4 | 115 | 79.99276893 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
